HealthDay News — The prevalence of post-COVID-19 condition (PCC) was 8.4% among US adults in 2023, according to a research letter published online in JAMA Network Open.

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound is a dual ...

Clinicians should identify barriers to treatment and improving clinical influenza testing, providing antiviral treatment for children with influenza-associated hospitalizations with >2 days of ...

GSK has made the decision to withdraw Jesduvroq (daprodustat) from the US market. Approved in 2023, Jesduvroq, (HIF-PHI), is ...

Significant changes from previous guideline include recommendation that only FSH >25 IU required for POI diagnosis.

The Food and Drug Administration (FDA) has approved Steqeyma ® (ustekinumab-stba), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases in adults and ...

Across the last 3 decades, worldwide age-standardized stroke burden rates have declined although some areas have seen increases in disability-adjusted life year rates and age-standardized prevalence, ...

The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk of hepatotoxicity, following the Food and Drug Administration’s review of a ...